IN THE NEWS
-
INTEGRAGEN - S1 2020 SALES OF €4.7M UP +13 % AND CASH POSITION OF €5.8M
IntegraGen today announces its sales, unaudited, for the first half of 2020. Unaudited sales for the first half amounted to €4,706K, up... Read More
-
INTEGRAGEN ACHIEVES CE MARKING FOR MERCURY™, A CLOUD-BASED SOFTWARE APPLICATION FOR INTERPRETING MOLECULAR DATA FROM CANCER PATIENTS' TUMORS
IntegraGen announces the CE marking of its cloud-hosted online software application, MERCURY™ for tumor molecular data interpretation. This CE marking strengthens IntegraGen's ability to sell MERCURY... Read More
-
INTEGRAGEN UPDATE - ALWAYS OPEN FOR YOUR PROJECTS
IntegraGen follows government recommendations and precautionary measures related to the COVID-19 crisis. As a leading provider of genomic services, we are committed to... Read More
LATEST NEWS
-
INTEGRAGEN ANNOUNCES AN AGREEMENT WITH A LEADING US CANCER CENTER FOR THE USE OF MERCURY™, THE ONCOLOGY SEQUENCING DATA INTERPRETATION AND REPORTING TOOL
IntegraGen announced today that the Dana Farber Cancer Institute will use MERCURYTM, IntegraGen's proprietary software, to... Read More
-
COVID-19: MEASURES TO PROTECT EVERYONE AND ENSURE YOUR PROJECTS RUN SMOOTHLY
Dear IntegraGen customers and partners, We care about your satisfaction and understand that all... Read More
-
INTEGRAGEN RENEWS PARTNERSHIP AGREEMENT WITH INSTITUT PASTEUR FOR HIGH THROUGHPUT SEQUENCING IN MICROBIOLOGY
IntegraGen today announced the renewal, until December 2021, of its partnership agreement with the Institut Pasteur... Read More
-
INTEGRAGEN PRESENTS RESULTS OF A STUDY EXTENDING THE IMPACT OF MIR-31 EXPRESSION MEASUREMENT TO STAGE III COLON CANCER PATIENTS AT ESMO 2018
Analysis of samples from the PETACC 8 phase III clinical trial shows that the... Read More
